Long-term safety of the stem cell releasing compound plerixafor for peripheral stem cell collection in myeloma patients

Hematol Oncol. 2023 Aug;41(3):583-586. doi: 10.1002/hon.3055. Epub 2022 Aug 6.

Authors

Melanie Maechler¹, Ulrike Bacher², Michael Daskalakis², Henning Nilius³, Michael Nagler³, Behrouz Mansouri Taleghani², Barbara Jeker¹, Thomas Pabst¹

Affiliations

¹ Department of Medical Oncology, Bern University Hospital, University of Bern, Bern, Switzerland.
² Department of Hematology and Central Hematology Laboratory, Bern University Hospital, University of Bern, Bern, Switzerland.
³ University Institute of Clinical Chemistry, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.

PMID: 35920140
DOI: 10.1002/hon.3055

No abstract available

Keywords: autologous stem cell transplantation (ASCT); long-term safety; multiple myeloma; plerixafor; stem cell mobilization.

Publication types

Letter

MeSH terms

Benzylamines
Granulocyte Colony-Stimulating Factor
Hematopoietic Stem Cell Mobilization
Hematopoietic Stem Cell Transplantation*
Heterocyclic Compounds* / pharmacology
Heterocyclic Compounds* / therapeutic use
Humans
Multiple Myeloma* / therapy
Peripheral Blood Stem Cell Transplantation*
Peripheral Blood Stem Cells*
Transplantation, Autologous

Substances

Heterocyclic Compounds
Granulocyte Colony-Stimulating Factor
Benzylamines

Grants and funding

SCL #38-167/SWISS CANCER LEAGUE